Trial · NCT07883798
Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions
NCT07883798, Recruiting, Affidea Nu-med Center of Oncological DIagnostics and Therapy
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions. Trials, record NCT07883798. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883798
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions
- NCT number
- NCT07883798
- Status
- Recruiting
- Enrollment
- 500 participants, estimated
- Lead sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
- Conditions
- Cervical Cancer, Gynecologic Cancer, Endometrial Cancer, Uterine Cancer, Uterine Sarcoma, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Vulvar Cancer, Vaginal Cancer
- Interventions
- Routine-care metastasis-directed radiotherapy
- First posted
- 2026-10-20
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Radiographic progression-free survival (rPFS) | From the first qualifying radiotherapy fraction or brachytherapy application (T0-RT), assessed for up to 5 years. | Time from the first qualifying radiotherapy fraction or brachytherapy application (T0-RT) to first radiographic progression at any site or death from any cause. Participants without an event are censored at the last reliable radiographic assessment. Clinical progression without imaging is recorded separately and considered in sensitivity analyses. |
| Secondary | Polymetastatic progression-free survival: classical threshold (PMFS-C5) | From the first qualifying radiotherapy fraction or brachytherapy application (T0-RT), assessed for up to 5 years. | Time from the first qualifying radiotherapy fraction or brachytherapy application (T0-RT) to more than 5 total active metastatic lesions, diffuse or uncountable disease, or death. Evaluated only in participants with 1-5 active metastatic lesions at the qualifying oligometastatic disease assessment (T0-OMD). The threshold uses total active metastatic burden, not only newly detected lesions. |
| Secondary | Polymetastatic progression-free survival: extended threshold (PMFS-E10) | From the first qualifying radiotherapy fraction or brachytherapy application (T0-RT), assessed for up to 5 years. | Time from the first qualifying radiotherapy fraction or brachytherapy application (T0-RT) to more than 10 total active metastatic lesions, diffuse or uncountable disease, or death. Evaluated in the positron emission tomography (PET)-defined cohort with 1-10 lesions. The expanded positron emission tomography-defined polymetastatic progression threshold (PMD-E10) status is indeterminate when follow-up imaging cannot assess the threshold, unless more than 10 lesions or diffuse disease is unequivocal. |
| Secondary | Time to loss of the oligometastatic state (TLOMS) | From the first qualifying radiotherapy fraction or brachytherapy application (T0-RT), assessed for up to 5 years. | Time from the first qualifying radiotherapy fraction or brachytherapy application (T0-RT) to loss of the oligometastatic state through progression to the applicable polymetastatic threshold or diffuse disease. Death is treated as a competing event in the disease-state estimand. |
| Secondary | Systemic therapy start or switch-free survival (SST-FS) | From the first qualifying radiotherapy fraction or brachytherapy application (T0-RT), assessed for up to 5 years. | Time from the first qualifying radiotherapy fraction or brachytherapy application (T0-RT) to initiation of systemic anticancer treatment, a change in treatment line, escalation of the systemic strategy, or death. Event rules depend on the baseline systemic-treatment setting. |
| Secondary | Overall survival (OS) | From the first qualifying radiotherapy fraction or brachytherapy application (T0-RT), assessed for up to 5 years. | Time from the first qualifying radiotherapy fraction or brachytherapy application (T0-RT) to death from any cause. |
| Secondary | Treated-lesion local control | From the first radiotherapy fraction or brachytherapy application to each lesion, assessed for up to 5 years. | Time from the first radiotherapy fraction or brachytherapy application to the individual lesion to unequivocal in-field progression. Death without lesion progression is treated as a competing event. Lesions are assessed individually. |
| Secondary | Pattern of first progression | At first progression after the first qualifying radiotherapy fraction or brachytherapy application (T0-RT), during follow-up of up to 5 years. | Description of first progression by anatomical site, number of active lesions, detection modality, local feasibility of subsequent metastasis-directed therapy, and oligometastatic or polymetastatic disease status. |
| Secondary | Systemic therapy-free survival (STFS) | From the first qualifying radiotherapy fraction or brachytherapy application (T0-RT), assessed for up to 5 years. | Among participants without active systemic treatment at the first qualifying radiotherapy fraction or brachytherapy application (T0-RT), time to initiation of any systemic anticancer treatment or death. |
| Secondary | Time to next systemic therapy line (TTNSL) | From the first qualifying radiotherapy fraction or brachytherapy application (T0-RT), assessed for up to 5 years. | Time from the first qualifying radiotherapy fraction or brachytherapy application (T0-RT) to the first new systemic treatment line after the index strategy. Continuation of a regimen started as part of the index strategy is not an event until treatment is changed or escalated. |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883798
GET https://conductscience.org/api/trials/v1/NCT07883798/registered?page=2